Description
Description:
Rolimus is a medication manufactured by Cipla Ltd. It contains the active ingredient Everolimus. Each tablet of Rolimus typically contains 10 mg of Everolimus.
Active Ingredient:
Everolimus: Everolimus belongs to the class of medications known as mammalian target of rapamycin (mTOR) inhibitors. It is used in the treatment of various types of cancer, including kidney cancer, breast cancer, pancreatic neuroendocrine tumors, and certain types of brain tumors. Everolimus works by inhibiting the activity of mTOR, a protein kinase involved in cell growth, proliferation, and angiogenesis. By inhibiting mTOR, Everolimus slows down the growth and spread of cancer cells.
Manufacturer:
Cipla Ltd.: Cipla Ltd. is the manufacturer of Rolimus. It is a leading global pharmaceutical company known for producing high-quality generic medications and innovative pharmaceutical products.
Indications:
Rolimus, containing Everolimus, is indicated for the treatment of various types of cancer, including:
- Advanced renal cell carcinoma (kidney cancer)
- Hormone receptor-positive, HER2-negative breast cancer
- Pancreatic neuroendocrine tumors (PNET)
- Advanced gastrointestinal or lung neuroendocrine tumors
- Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis
- Renal angiomyolipoma associated with tuberous sclerosis
Rolimus may be used alone or in combination with other cancer medications, depending on the specific type and stage of cancer being treated. It is typically prescribed by an oncologist or healthcare provider experienced in cancer treatment.
Dosage and Administration:
The dosage of Rolimus (Everolimus) and the treatment schedule may vary depending on factors such as the type of cancer being treated, the patient’s overall health condition, and other medications being used in combination therapy. Rolimus is usually taken orally once daily, with or without food, as directed by the prescribing healthcare provider.
Side Effects:
Common side effects associated with Rolimus (Everolimus) may include:
- Fatigue
- Weakness
- Loss of appetite
- Nausea and vomiting
- Diarrhea
- Mouth sores
- Rash or skin changes
- Infections
- Changes in blood cell counts (anemia, leukopenia, thrombocytopenia)
Some patients may experience more serious side effects such as allergic reactions, severe infections, liver or kidney problems, high blood sugar, or lung problems. It is important to report any unusual or severe side effects to the healthcare provider promptly.
Precautions:
Before starting treatment with Rolimus (Everolimus), patients should inform their healthcare provider about any underlying medical conditions, allergies, or medications they are currently taking. Everolimus may interact with certain medications or medical conditions, so it is essential to discuss potential drug interactions and precautions with the healthcare provider. Pregnant or breastfeeding women should avoid using Rolimus due to potential risks to the fetus or infant. Regular monitoring of blood counts, liver function, kidney function, and blood glucose levels may be necessary during treatment with Rolimus to monitor for potential adverse effects. Rolimus should only be used under the supervision of a qualified healthcare professional experienced in the treatment of cancer.
Reviews
There are no reviews yet.